NCT02061683View on ClinicalTrials.gov

A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

April 19, 2010

Primary Completion Date

June 24, 2011

Study Completion Date

June 24, 2011

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

Bimatoprost 0.03%

Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.

Trial Locations (1)

Unknown

Shanghai

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY